PDSB (PDS Biotechnology Corporation) Quick Liquidity

PDS Biotechnology focuses on developing innovative tumor vaccines, leveraging Versamune and a team of researchers with option-based incentives. This asset value chart reflects a trend where the current figure is 0.55. Since the company is in the testing phase, operating leverage remains negative. Business flexibility is ensured by fully outsourcing production and trials to external contractors without capital expenditures.

For PDS Biotechnology, a leader in the development of cancer immunotherapy platforms, access to operational resources excluding slow-moving inventories is critically important. This ratio measures the company's ability to meet short-term obligations using only cash and accounts receivable, allowing a real-time assessment of the issuer's actual financial stability and bankruptcy risk through the monitoring of quick liquidity.